Welcome to LookChem.com Sign In|Join Free
  • or
(R)-7-bromo-N-(4-hydroxyphenethyl)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxamide is a complex chemical compound characterized by its unique molecular structure. It features a bromine atom, a hydroxyphenethyl group, and a tetrahydropyrroloquinazoline core, all connected through a carboxamide functional group. (R)-7-bromo-N-(4-hydroxyphenethyl)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxamide's stereochemistry as a (R)-enantiomer suggests a specific three-dimensional arrangement of atoms, which could influence its potential biological activity and pharmacological properties. Due to its intricate structure, (R)-7-bromo-N-(4-hydroxyphenethyl)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxamide may hold promise for medicinal research and development; however, further studies are required to ascertain its specific applications and effects.

2435557-99-4

Post Buying Request

2435557-99-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2435557-99-4 Usage

Uses

Used in Pharmaceutical Research and Development:
(R)-7-bromo-N-(4-hydroxyphenethyl)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxamide is used as a potential candidate in pharmaceutical research and development for its complex molecular structure and stereochemistry. (R)-7-bromo-N-(4-hydroxyphenethyl)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxamide's unique arrangement of atoms and functional groups may offer novel pharmacological properties, making it a valuable asset in the search for new therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (R)-7-bromo-N-(4-hydroxyphenethyl)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxamide is used as a starting point for the design and synthesis of new drugs. Its intricate structure and stereochemistry may provide insights into the development of more effective and targeted therapeutics.
Used in Biological Activity Studies:
(R)-7-bromo-N-(4-hydroxyphenethyl)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxamide is utilized in biological activity studies to explore its potential interactions with biological targets, such as receptors, enzymes, or other proteins. Understanding these interactions can help researchers determine the compound's suitability for various therapeutic applications.
Used in Drug Design and Optimization:
In the context of drug design and optimization, (R)-7-bromo-N-(4-hydroxyphenethyl)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxamide serves as a structural template for the development of new drugs. Its unique features may be leveraged to improve the potency, selectivity, and pharmacokinetic properties of future therapeutic agents.

Check Digit Verification of cas no

The CAS Registry Mumber 2435557-99-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,4,3,5,5,5 and 7 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 2435557-99:
(9*2)+(8*4)+(7*3)+(6*5)+(5*5)+(4*5)+(3*7)+(2*9)+(1*9)=194
194 % 10 = 4
So 2435557-99-4 is a valid CAS Registry Number.

2435557-99-4Downstream Products

2435557-99-4Relevant academic research and scientific papers

Design, synthesis and bioevaluation of 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxylic acid derivatives as potent neuroprotective agents

Zhang, Linkui,Zhao, Ying,Wang, Jian,Yang, Donglin,Zhao, Chenwen,Wang, Changli,Ma, Chao,Cheng, Maosheng

, p. 27 - 38 (2018)

Diverse of 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxylic acid derivatives were designed, synthesized and evaluated for their neuroprotective activity against NMDA-induced cytotoxicity in vitro, and 5q exhibited excellent neuroprotective activity. The compound 5q was selected for further investigation. We found that 5q could attenuate Ca2+ influx induced by NMDA, meanwhile, 5q could suppress the NR2B up-regulation and increase p-ERK1/2 expression. The molecular docking results showed that 5q might fit well in the binding pocket of 4 and interact with some key residues in the binding pocket of 1 simultaneously. Besides, 5q exhibited acceptable metabolic stability. These results suggested that 5q was a promising lead for further development of new potent and orally bioavailable NR2B-selective NMDAR antagonists.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 2435557-99-4